相关参考文献
注意：仅列出部分参考文献，下载原文获取全部文献信息。Adverse Events Do Not Outweigh Benefits of Combination Therapy for Crohn's Disease in a Decision Analytic Model
Corey A. Siegel et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2012)
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
Edouard Louis et al.
GASTROENTEROLOGY (2012)
Development of a new immunoassay for the accurate determination of anti-infliximab antibodies in inflammatory bowel disease
Hirotsugu Imaeda et al.
JOURNAL OF GASTROENTEROLOGY (2012)
Early clinical remission and normalisation of CRP are the strongest predictors of efficacy, mucosal healing and dose escalation during the first year of adalimumab therapy in Crohn's disease
L. S. Kiss et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2011)
Role of Thiopurine and Anti-TNF Therapy in Lymphoma in Inflammatory Bowel Disease
Lisa J. Herrinton et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2011)
Discontinuation of infliximab and potential predictors of persistent low disease activity in patients with early rheumatoid arthritis and disease activity score-steered therapy: subanalysis of the BeSt study
M. van den Broek et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Malignancies associated with tumour necrosis factor inhibitors in registries and prospective observational studies: a systematic review and meta-analysis
Xavier Mariette et al.
ANNALS OF THE RHEUMATIC DISEASES (2011)
Advanced Age Is an Independent Risk Factor for Severe Infections and Mortality in Patients Given Anti-Tumor Necrosis Factor Therapy for Inflammatory Bowel Disease
Mario Cottone et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
A Systematic Review of Factors That Contribute to Hepatosplenic T-Cell Lymphoma in Patients With Inflammatory Bowel Disease
David S. Kotlyar et al.
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2011)
Meta-analysis: efficacy and safety of combination therapy of infliximab and immunosuppressives for Crohn's disease
Ziwei Lin et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Hepatosplenic T-cell lymphoma in patients receiving TNF-α inhibitor therapy: expanding the groups at risk
Deepak Parakkal et al.
EUROPEAN JOURNAL OF GASTROENTEROLOGY & HEPATOLOGY (2011)
Increased Risk of Nonmelanoma Skin Cancers Among Individuals With Inflammatory Bowel Disease
Harminder Singh et al.
GASTROENTEROLOGY (2011)
Increased Risk for Nonmelanoma Skin Cancers in Patients Who Receive Thiopurines for Inflammatory Bowel Disease
Laurent Peyrin-Biroulet et al.
GASTROENTEROLOGY (2011)
Early use of immunosuppressives or TNF antagonists for the treatment of Crohn's disease: time for a change
Ingrid Ordas et al.
GUT (2011)
Anti-TNF therapy is associated with an increased risk of serious infections in patients with rheumatoid arthritis especially in the first 6 months of treatment: updated results from the British Society for Rheumatology Biologics Register with special emphasis on risks in the elderly
James B. Galloway et al.
RHEUMATOLOGY (2011)
Maintenance of clinical benefit in Crohn's disease patients after discontinuation of infliximab: long-term follow-up of a single centre cohort
A. W. G. Waugh et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2010)
Predictors of Infliximab Failure After Azathioprine Withdrawal in Crohn's Disease Treated With Combination Therapy
Abderrahim Oussalah et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Continuing Medical Education: February 2010
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
Waqqas Afif et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2010)
Discontinuation of infliximab after attaining low disease activity in patients with rheumatoid arthritis: RRR (remission induction by Remicade in RA) study
Y. Tanaka et al.
ANNALS OF THE RHEUMATIC DISEASES (2010)
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease.
Jean Frederic Colombel et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD-subgroup analyses across four randomized trials
G. R. Lichtenstein et al.
ALIMENTARY PHARMACOLOGY & THERAPEUTICS (2009)
Adverse Events Associated With Common Therapy Regimens for Moderate-to-Severe Crohn's Disease
Josh Marehbian et al.
AMERICAN JOURNAL OF GASTROENTEROLOGY (2009)
How to dose infliximab in rheumatoid arthritis: new data on a serious issue
Ronald F. van Vollenhoven
ANNALS OF THE RHEUMATIC DISEASES (2009)
Long-term safety of infliximab for the treatment of inflammatory bowel disease: a single-centre cohort study
H. Fidder et al.
GUT (2009)
Lymphoproliferative disorders in patients receiving thiopurines for inflammatory bowel disease: a prospective observational cohort study
Laurent Beaugerie et al.
LANCET (2009)
Sustained effect after lowering high-dose infliximab in patients with rheumatoid arthritis: a prospective dose titration study
B. J. F. van den Bemt et al.
ANNALS OF THE RHEUMATIC DISEASES (2008)
Withdrawal of immunosuppression in Crohn's disease treated with scheduled infliximab maintenance: a Randomized trial
Gert Van Assche et al.
GASTROENTEROLOGY (2008)
Risk factors for opportunistic infections in patients with inflammatory bowel disease
Murat Toruner et al.
GASTROENTEROLOGY (2008)
The safety of infliximab, combined with background treatments, among patients with rheumatoid arthritis and various comorbidities - A large, randomized, placebo-controlled trial
R Westhovens et al.
ARTHRITIS AND RHEUMATISM (2006)
Increased risk of lymphoma among inflammatory bowel disease patients treated with azathioprine and 6-mercaptopurine
A Kandiel et al.
GUT (2005)
The safety profile of infliximab in patients with Crohn's disease: The Mayo Clinic experience in 500 patients
JF Colombel et al.
GASTROENTEROLOGY (2004)
分享论文
